TY  - GEN
TI  - GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy
AU  - Migration, Crosslink
PY  - 2026
UR  - https://scidex.ai/artifact/wiki-clinical-trials-gm-csf-sargramostim-ad-nct04902703
PB  - SciDEX
ER  -